Radioangiocardiogram monitoring in patients receiving bisantrene.
Due to the tricyclic structural similarity between the anthracyclines and a new anthracene bishydrazone derivative, bisantrene, changes in myocardial function as detected by radionuclide angiography were sought in early phase I-II trials of the drug. Overall, there appear to be no changes in ejection fraction when determined 24 hours postinfusion, or when determined after low cumulative doses of bisantrene.